Investigating hexose-6-phosphate dehydrogenase in the control of skeletal muscle function and carbohydrate metabolism

Lead Research Organisation: University of Birmingham
Department Name: Clinical and Experimental Medicine

Abstract

This proposal aims to understand more about the metabolic pathways that mammals use to derive energy from the glucose found in food and utilise it in muscle. Muscle is a vital tissue for controlling body glucose levels, which when elevated can be detrimental. We currently live in a time when glucose and calorie rich food is widely available (the consequences of too much glucose and calories are seen in obesity and diabetes). However, the underlying biological consequences our changing diets has are poorly understood so it is becoming increasingly important to gain a better understanding of the fundamental physiological processes that regulate glucose and energy metabolism in muscle. Our recent work has identified two enzymes in muscle that control important aspects of glucose metabolism. The first enzyme called 11b-HSD1 controls steroid hormone levels, which have potent effects on glucose usage in response to stress. The second enzyme called H6PDH metabolises glucose. What is interesting is that H6PDH can control 11b-HSD1 depending upon the supply of glucose, however, steroid hormones can control glucose levels, highlighting that these enzymes can control each others functions. This interaction between glucose and steroid hormone metabolism is very novel and our recent preliminary findings indicate that it plays an important role, therefore we wish to explain the underlying biology in muscle. To achieve this, we will manipulate H6PDH and 11b-HSD1 levels in muscle to varying degrees (e.g. simultaneously trying to increase steroid hormone metabolism, decrease glucose metabolism) using cells in culture and observe the consequences on cellular metabolism. These experiments will help to guide our use of mice with genetically modified H6PDH and 11b-HSD1 genes, which will allow a true assessment of their roles in a more physiologically relevant system. The experiments will test how steroid hormones and glucose metabolism can be manipulated and derive the true function of these systems in helping to control muscle tissues energy requirements. Ultimately, we hope these basic and fundamental studies will help other scientists, pharmaceutical companies and medical practitioners to improve their scientific knowledge and research. Understanding how energy metabolism is controlled will also aid improvements society's knowledge and hopefully create future health benefits.

Technical Summary

Mammalian carbohydrate homeostasis is of primary importance to energy provision and the action of insulin on metabolism. In muscle, glucose is phosphorylated to glucose-6-phosphate (G6P) and used by multiple pathways including ATP generation. We have identified the enzyme H6PDH, within the sarcoplasmic reticulum (SR) of muscle which can metabolise G6P and may have an important role in its utilisation. One known function of H6PDH is to generate NADPH cofactor which allows the enzyme 11b-HSD1 to produce intracellular glucocorticoids (GCs), hormones that control metabolism by regulating gene transcription. H6PDH knockout mice (H6PDHKO) show the obligate nature of 11b-HSD1 for H6PDH. In the absence of H6PDH, 11b-HSD1 inactivates GCs, leading to blunted responses to GCs. Interestingly H6PDHKO mice also develop a vacuolating myopathy associated with activation of ER stress pathways and alterations in local and global glucose homeostasis. We hypothesise that changes in muscle H6PDH expression can modulate G6P and ATP levels that affect local and whole body metabolism which can be independent of GCs and 11b-HSD1. Aims - Determine the contributions of H6PDH mediated G6P and GC metabolism to glucose homeostasis - Define the contribution of H6PDH G6P metabolism to myopathy and glucose homeostasis in H6PDKO mice - Elucidate the relationship between H6PDH expression in muscle and the ER stress response This study will define the metabolic role of H6PDH in muscle and how it relates to GC metabolism, insulin sensitivity and glucose homeostasis and explore the observations linking aberrant ER metabolism to defective muscle structure and function. The proposed research will determine new and fundamental mechanisms of carbohydrate metabolism in highly relevant systems that have important benefits for our understanding of mammalian metabolic physiology.

Publications

10 25 50
 
Description The major aspects of objectives of the award were met. The award delineated new aspects of muscle energy metabolism and physiology that will inform our understanding of ageing metabolic decline. The award Identified new systems that control muscle function in response to metabolic stress such as in obesity, diabetes, hormonal imbalance or other diseases. Clarified a key mechanism that may explain how an individual may succumb to glucocorticoid excess and suggest a therapeutic option.

The award has led to basic laboratory research being translated into clinical trials that have facilitated a better understanding of human physiology in health and disease. The following registered trials are directly attributable to outcomes of this award-
- Targeting Iatrogenic Cushing's Syndrome With 11ß-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI)- ClinicalTrials.gov Identifier: NCT03111810
- Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype (NADMet)- ClinicalTrials.gov Identifier: NCT02950441

The award has enhanced our understanding of muscle energy metabolism and supported the generation of data that formed the basis of research support awarded by the Wellcome Trust to continue the theme of the work- focussing on muscle health in ageing.
Employability of those funded by the award was enhanced- all post holders going to up take up a postdoctoral position, a tenured Senior Lecturer position and tenured Professor position.
Exploitation Route ClinicalTrials.gov- NCT03111810 and ClinicalTrials.gov- NCT02950441 are good evidence of major onward achievements of the award in that basic research finds utility to understand human health and disease. These trials may go on to form the basis for further large scale trials to better tailor treatments for disease. Our follow on funding from the Wellcome Trust supported continued basic discovery science using the full range experimental models- including humans. Clinical researchers are now able to use these discoveries to design clinical in population based studies and interventions. Clinical researchers are also interested in the wider implications of our achievements and tools in defining novel physiology of health and disease across a wider range of conditions, increasing the reach of this fundamental research. Finally, industry is using the achievements of the award to support academic research in areas that could generate therapies. Clinicians may which to use the data and resources we have generated to invest in trials examining the effectiveness of treatment options for Cushing's disease.
Sectors Education,Healthcare,Pharmaceuticals and Medical Biotechnology

 
Description Heath and well being treatment potential in a rare disease (Cushing's disease/ syndrome)- if the right centres and researchers wish to take these published findings forward in to clinical research then this could be very beneficial. New knowledge has been generated and can be used as the information base for new science to be conducted.An example is the following entry on ClicnialTrials.gov- Targeting Iatrogenic Cushing's Syndrome With 11ß-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI)- ClinicalTrials.gov Identifier: NCT03111810
First Year Of Impact 2017
Sector Education,Healthcare,Pharmaceuticals and Medical Biotechnology
Impact Types Societal,Economic

 
Description 1x MRC/University of Birmingham studentships
Amount £65,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 10/2013 
End 09/2016
 
Description 2x MRC/University of Birmingham studentships
Amount £113,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 10/2010 
End 09/2014
 
Description Exploring beta cell reprogramming by glucocorticoids
Amount £187,330 (GBP)
Funding ID 17/0005681 
Organisation Diabetes UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2018 
End 01/2021
 
Description Pathways Regulating Intramyocellular Insulin Sensitivity and Metabolism in Health and Disease-PRIISM-HD.
Amount £186,000 (GBP)
Organisation Marie Curie 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2017 
End 11/2020
 
Description Project grant
Amount £450,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 05/2013 
End 04/2016
 
Description Project grant
Amount £235,000 (GBP)
Organisation Versus Arthritis 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2012 
End 05/2015
 
Description Selective CYP11B1 inhibitors as a novel treatment option for endogenous cortisol excess
Amount £248,078 (GBP)
Funding ID MR/R002339/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 01/2018 
End 11/2022
 
Description The role of CD248 (Endosialin) in adipocyte differentiation and fat formation
Amount £425,534 (GBP)
Organisation AstraZeneca 
Sector Private
Country United Kingdom
Start 04/2019 
End 03/2022
 
Description Wellcome Trust Senior Research Fellowship In Basic Biomedical Sciecne
Amount £1,606,529 (GBP)
Funding ID 104612/Z/14/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2014 
End 10/2019
 
Title HSD11B1 floxed allele 
Description Allows the tissue specific inspection of the function of the HSD11B1 gene in mice through genetic recombination methods. 
Type Of Material Model of mechanisms or symptoms - mammalian in vivo 
Year Produced 2012 
Provided To Others? Yes  
Impact Supported successful grant and personal fellowship application and publications with translational implications for human health 
 
Description ChromaDex and Nicotinamide Riboside (NR) MTA 
Organisation ChromaDex
Country United States 
Sector Private 
PI Contribution Initiated collaboration as research indicated that Nicotinamide Riboside made by ChromaDex will have an important bearing on our results. We contacted them and we have entered an MTA to be supplied with NR compound.
Collaborator Contribution ChromaDex have provided, under an MTA NR compound for use in experiments as described in the MTA.
Impact Has supported my research group being funded through the attainment of a Wellcome Trust Senior Research Fellowship- for which ChromaDex were a signed collaborator.
Start Year 2013
 
Description Think tank late night engagement 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Most recently the Lavery lab collaborated with the Thinktank Birmingham Science Museum to be part of a special late-night event that saw over 350 attendees visit the museum 'after hours' to engage with scientists in an approachable and friendly environment. Importantly, this event was free, giving young and old people who might not otherwise engage with science an opportunity to do so as part of an evening mixing science and art.
Year(s) Of Engagement Activity 2019
URL https://garethlaverylab.com/explore-our-site/engagement/